Search results
Results from the WOW.Com Content Network
As an inactivated vaccine, CoviVac uses a more traditional technology that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 strain AYDAR-1 was isolated by the Chumakov Center at the Russian Academy of Sciences and used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in ...
COVID-19 pandemic in Russia: Target: Immunization against COVID-19: Participants: 81,580,140 people have received at least one dose (21 June 2022) [3] 74,311,072 people have been fully vaccinated (21 June 2022) [3] Outcome: 55.86% of the Russian population has received at least one dose of a vaccine [a] [3] [4] 50.88% of the Russian population ...
A real-world study with participants aged 60–79 years in Argentina found that the single-injection vaccine is 79% (95% CI, 75 – 82%) effective in preventing infections, 88% (95% CI, 80 – 92%) effective against hospitalization, and 85% (95% CI, 75 – 91%) against death. [8] A phase III clinical trial in Russia also found an efficacy of 79%.
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, [39] [42] such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be [needs update] prioritized distribution first within the UK and to the ...
During the coronavirus pandemic, Russia developed its own Sputnik V vaccine against COVID-19 and sold it to a number of countries, although domestically it ran up against widespread public ...
This Baltic nation is an oft-overlooked European gem. Its capital, Tallinn, gets the bulk of attention, but there are compelling things to find all over, from beaches to art, sauna culture to ...
In May 2017, the Institute announced that it would deliver 1,000 doses of its vaccine candidate, GamEvac-Combi, [8] to Guinea for Ebola testing. According to a Xinhua report, it was considered to be an approved Ebola vaccine, [9] although GamEvac-Combi was licensed only in Russia, and did not have a multinational license approved by the World Health Organization, as of November 2019.